Gelesis Holdings Shares Outstanding 2021-2022 | GLS

Gelesis Holdings shares outstanding from 2021 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Gelesis Holdings Annual Shares Outstanding
(Millions of Shares)
2021 7
2020 7
2019
Gelesis Holdings Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 63
2021-12-31 7
2021-09-30 7
2021-06-30 10
2021-03-31 6
2020-12-31
2020-09-30 7
2020-06-30 6
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.111B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $167.557B 10.19
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.634B 16.78
Biohaven Pharmaceutical Holding (BHVN) United States $10.186B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.637B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.40
Emergent Biosolutions (EBS) United States $1.570B 6.72
Myovant Sciences (MYOV) United Kingdom $1.212B 0.00
Zymeworks (ZYME) Canada $0.325B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00